Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Celltrion biopharmaceutical company headquartered in Incheon, South Korea, recently signed a deal with San Jose, California-based biotherapeutics company. They have teamed up to jointly carry out research and development of an oral antibody medicine.
Celltrion and Rani Therapeutics named their project RT-111 and they will work together to create the said drug with ustekinumab which is an autoimmune ingredient. As per Pulse News, the medicine is for oral treatment and mentioned that ustekinumab is being sold under the name of Stelara by Janssen Pharmaceuticals.
This is normally used for treating ulcerative colitis and Crohn’s disease. For this project, the companies will use it to develop an antibody medicine.
The US-based biotherapeutics firm has the technology to turn intravenous and subcutaneous injection-type proteins and antibody therapies into oral medicines. And under the agreement, Celltrion will be supplying its biosimilar CT-P43 referencing Stelara to Rani Therapeutic‘s clinical and non-clinical tests for RT-111.
The deal also states that the latter has a preferential right to develop and bring medicine to the global market. It was noted that ustekinumab has already been approved in the United States so it can be freely used as an ingredient in RT-111.
“We are delighted to be partnering with Celltrion, a leader in biosimilars and biologics manufacturing, on RT-111,” Rani Therapeutics’ chief executive officer, Talat Imran, said in a press release. “This agreement is a validation of our RaniPill oral drug delivery technology, which has already performed well in two separate Phase 1 trial of RT-101 and RT-102, respectively.”
The CEO added, “We value Celltrion as the exclusive provider of ustekinumab biosimilar for our RT-111 program and look forward to sharing the results of our study in due course, and potentially broadening our partnership with Celltrion.”
Celltrion’s head of medical science unit, Kim Sung Hyun, also commented on its new partnership deal with Rani by saying, “Celltrion strives to address unmet needs of patients and partnering with Rani offers the opportunity to replace painful injections with a pill.”
